Most companies only bite the bullet and downsize when disaster is imminent. But after raising $32 million from private investors, Cell Therapeutics Inc. is proactively restructuring as it prepares to go into pivotal clinical trials.

The company last week announced a $6.4 million second round closing, adding to the $25.6 million initially raised in March.